cobas® CT/NG Test

Qualitative nucleic acid test for use on the cobas® 5800/6800/8800 Systems

IVD For in vitro diagnostic use.
cobas CT/NG
Proven efficiency, giving you the freedom to do more

With STI rates on the rise1cobas® CT/NG on the cobas 5800/6800/8800 systems provides a solution to meet the growing demand for CT/NG Testing, delivering exceptional assay performance, providing broader information for improved patient care decisions, and enabling simplicity and flexibility to support varying throughput and workflow requirements.

Features and benefits

Exceptional assay performance

  • The Dual-Target approach of cobas® CT/NG of both the genomic and cryptic plasmid DNA of Chlamydia trachomatis, ensures inclusion of nvCT strains for a highly sensitive test.
  • The use of two sets of primers targeting the highly conserved direct repeat region (DR-9) and a conserved sequence variant amplify and detect both wild type and variant versions of Neisseria gonorrhoeae.

Simplicity and flexibility to meet varying throughput and workflow requirements

  • Highest throughput molecular test for CT/NG on the market.
  • Continuous loading of samples with no pre-sorting required for mixed test requests.
  • Simultaneous processing of multiple tests from the same patient sample.
  • Full automation and process control of all STI tests onto a single platform including LDTs­­.

Chlamydia trachomatis

RMD_Chlamydia trachomatis

Neisseria gonorrhoeae

RMD_ Neisseria gonorrhoea
Would you like to know more about the cobas® CT/NG test?

Please submit your information in the following form to be contacted by a Roche representative with more details.

Form Successfully Submitted!
Thank you for your submission!
Intended use

Intended use

cobas® CT/NG for use on the cobas® 5800/6800/8800 Systems is an automated, qualitative in vitro nucleic acid diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens (collected in a clinical setting), and clinician-collected vaginal swab specimens, endocervical swab specimens, oropharyngeal (throat) swab specimens and anorectal swab specimens all collected in cobas® PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.



Registration status


Related systems

cobas 5800
cobas® 5800 System

Empowering laboratories to balance productivity, efficiency, and potential cost effectiveness with fully automated and standardized workflows, on demand testing and the proven reliability of Roche quality results..

Learn more
cobas® 6800 System

Unparalleled performance, absolute automation, and unmatched flexibility. Meet the needs of molecular testing today and experience the freedom to explore the possibilities for tomorrow.

Learn More
cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.

Learn More


  1. U.S. STI Epidemic Showed No Signs of Slowing in 2021 – Cases Continued to Escalate. Centers for Disease Control and Prevention. (Accessed January 2023.)


Detailed Specifications

Ordering Information

Compatible Instruments


    Technical Documents

    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later